Daily Newsletter

08 September 2023

Daily Newsletter

08 September 2023

Ohh-Med Medical sets up shop in the UK for erectile dysfunction device

A nonpharmaceutical treatment for erectile dysfunction has been launched in the UK, expanding the reach of the Vertica medical device.

Kiays Khalil September 07 2023

Israeli medtech startup Ohh-Med Medical is breaking into the UK market with the launch of Ohh-Med UK - a fully owned subsidiary.

The branch of operations will be based in London and will run a call centre for customer sales and support of Vertica, a medical device to treat long term erectile dysfunction (ED).

The device to treat ED is the company’s lead product, a non-invasive at home treatment for ED that uses radiofrequency technology to rejuvenate the natural erectile mechanism by improving collagen quality in the penile erectile tissues.

Discussing the Ohh-Med expansion, Ohh-Med CEO Daniel Lischinsky said: “Our experience in Israel selling thousands of medical devices through our sophisticated call centre and online shop has convinced me that we can copy this success in the United Kingdom, which is a huge market for Vertica.”

The device has been on sale since 2022 and in December it received the European Medical Devices Regulation (CE-MDR) approval allowing them to market throughout the EU.

Lischinsky added: “The results of our first clinical study, showing more than 85% success rate, have recently been published in a leading scientific journal, the IJIR – International Journal of Impotence Research, a member of the Nature group of publications. Now we have the scientific proof to support what our customers have been saying.”

Solutions for ED are becoming more popular and available to the public. In June 2023 Futura Medical’s over-the-counter (OTC) Eroxon gel for ED received US Food and Drug Administration (FDA) approval. 

Medical robotics set to witness robust growth in the next decade

GlobalData expects every segment of the medical robotics market to grow over the next decade, driven by the demands of high-volume procedures. Per GlobalData forecasts, the surgical robotics market is expected to grow at a CAGR of 8% by 2030. Surgical robots improve patient outcomes, reduce human error, and decrease the length of hospital stays. New surgical robot models will offer new surgical possibilities, such as micro-robots to address difficult-to-treat diseases.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close